-
Aug 1, 2024 | 
logicmag.io | Jane Chung
This essay was supposed to be about cleaning. I have a family history of cleaning work. My mom housekept and minded the front desk at a Holiday Inn throughout my childhood. My grandmother carried my brother to meet my dad at the office where he had a cleaning job; they all worked together to make good time.
-
Apr 8, 2024 | 
globenewswire.com | Samsung Bioepis |Jane Chung
The 5th edition explores some IRA implications on biosimilars along with latest price trends, biosimilars market share Marks one year of providing quarterly updates on US biosimilar market trends INCHEON, Korea, April 08, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its Second Quarter 2024 Biosimilar Market Report, which includes the latest Average Sales Price (ASP) information of all biosimilars and reference products available in the US market.
-
Apr 5, 2024 | 
morningstar.com | Jane Chung
INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer.
-
Mar 9, 2024 | 
globenewswire.com | Samsung Bioepis |Jane Chung
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as well as efficacy, safety and immunogenicity profiles were comparable between switching group and continuous reference product Humira group 52-week results from SB17 Phase 3 study demonstrated long-term efficacy, safety, and immunogenicity of SB17 compared to reference ustekinumab, including switching from ustekinumab to SB17...
-
Jan 17, 2024 | 
globenewswire.com | Samsung Bioepis |Jane Chung
Report highlights latest biosimilar pricing and market share status, including state of the adalimumab marketBiosimilar Deep Dive section illustrates patient benefit from lower adalimumab cost options using the estimated patient out-of-pocket costs between high WAC and low WAC optionsReport comes out every quarter after CMS publishes updated ASP values INCHEON, Korea, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.
-
Nov 30, 2023 | 
einnews.com | Jane Chung
/EIN News/ -- INCHEON, Korea, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara® (ustekinumab) in the United States (US). In the US, the license period will begin on February 22, 2025. The other terms of the agreement are confidential.
-
Oct 15, 2023 | 
globenewswire.com | Samsung Bioepis |Jane Chung
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced denosumab in healthy male study participantsPhase 3 study shows biosimilarity of SB16 with reference denosumab through equivalent efficacy and comparable pharmacodynamics (PD), PK, immunogenicity, and safety up to Month 12 INCHEON, Korea, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.
-
Oct 10, 2023 | 
globenewswire.com | Samsung Bioepis |Jane Chung
Details the latest quarterly information on biosimilar utilization and financial datapoints for the US biosimilar marketExplores key determinants influencing various degrees of biosimilar utilization INCHEON, South Korea, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released the Fourth Quarter 2023 Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States.
-
Jul 11, 2023 | 
einnews.com | Jane Chung
There were 678 press releases posted in the last 24 hours and 465,334 in the last 365 days. Details updated average sales price (ASP) trends and market share across all molecules for which biosimilars are available Includes Wholesale Acquisition Cost (WAC) trends of recently launched adalimumab biosimilars /EIN News/ -- INCHEON, Korea, July 11, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.
-
Apr 24, 2023 | 
markets.buffalonews.com | Samsung Bioepis |Jane Chung
SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56Switching group had similar efficacy and safety compared to the continuing groups without treatment-emergent issues such as loss of efficacy, increased adverse events, or increased immunogenicity INCHEON, Korea, April 24, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.
